Neuroscience company Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) disclosed on Monday that it has commenced a Phase 2 clinical trial for ACP-204, targeting hallucinations and delusions linked to Alzheimer's disease psychosis (ADP).
Over 6.5 million Americans with Alzheimer's face psychosis, affecting 30%. The company's global Phase 2 trial includes 318 patients assessing ACP-204 doses (30 mg and 60 mg) versus placebo, focusing on the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales (SAPS-H+D) total score at Week 6.
This trial seamlessly transitions into two Phase 3 studies, each enrolling about 378 ADP patients. Participants completing the study may join a long-term open-label extension.
Alzheimer's disease psychosis, impacting 30% of AD patients, lacks FDA-approved drugs. ACP-204, an inverse agonist at the 5-HT2A receptor, addresses this unmet medical need, highlighting Acadia's commitment to advancing neuroscience breakthroughs for conditions like schizophrenia, Prader-Willi syndrome and neuropsychiatric symptoms in CNS disorders.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI